Abstract
Disorders of sex development (DSD) are a generic definition including any problem noted at birth where the genitalia are atypical in relation to the chromosomes or gonads. The most important clinical problems in DSD comprise physical and psychological disturbances and the risk of gonadal tumor development. Germ cell tumor risk is lowest (<5%) in patients with defects in androgene action or synthesis (such as complete androgen insensitivity syndrome, 5α-reductase deficiency), whereas the highest risk (15%–60%) is observed in 46,XY gonadal dysgenesis. The presence of Y chromosomal material in the karyotype increases the risk for the development of gonadal tumors. The reported age of tumor development varies based on the etiology of DSD (gonadal dysgenesis, androgen insensitivity syndrome, androgen synthesis defects, mixed gonadal dysgenesis, etc.). In the past, early gonadectomy was recommended for all cases of 46,XY DSD, however, according to current approaches, gonadal tumor risk is predicted based on the molecular diagnosis and the timing of the gonadectomy depends on the result of molecular analysis. Until now, optimal protocol in the management of DSD is still controversial. In addition to that, safe and well-accepted guidelines are needed. There is limited number of prospective studies on timing of a gonadectomy in childhood and adolescence. Therefore, evidence-based data on timing and indications of gonadectomy in patients with DSD are needed. In this review, recent data regarding gonadal malignancy risk in DSD and recommendations on timing of gonadectomy are presented.
References
1. Hughes IA, Houk C, Ahmed SF, Lee PA. Consensus statement on management of intersex disorders. Arch Dis Child 2006;91: 554–63.10.1136/adc.2006.098319Search in Google Scholar PubMed PubMed Central
2. Witchel SF, Lee PA. Ambiguous genitalia. In: Sperling MA, editor. Pediatric endocrinology. Philadelphia: Saunders Elsevier, 2008:127–64.Search in Google Scholar
3. Crone J, Amann G, Gheradini R, Kirchlechner V, Fekete CN. Management of 46, XY partial gonadal dysgenesis – revisited. Wien Klin Wochenschr 2002;114:462–7.Search in Google Scholar
4. Mendoza N, Motos MA. Androgen insensitivity syndrome. Gynecol Endocrinol 2013;29:1–5.10.3109/09513590.2012.705378Search in Google Scholar PubMed
5. Reiner WG, Gearhart JP. Discordant sexual identity in some genetic males with cloacal exstrophy assigned to female sex at birth. N Engl J Med 2004;350:333–41.10.1056/NEJMoa022236Search in Google Scholar PubMed PubMed Central
6. Looijenga LH, Hersmus R, Oosterhuis JW, Cools M, Drop SL, et al. Tumor risk in disorders of sex development (DSD). Best Pract Res Clin Endocrinol Metab 2007;21:480–95.10.1016/j.beem.2007.05.001Search in Google Scholar PubMed
7. Pleskacova J, Hersmus R, Oosterhuis JW, Setyawati BA, Faradz SM, et al. Tumor risk in disorders of sex development. Sex Dev 2010;4:259–69.10.1159/000314536Search in Google Scholar PubMed
8. Cools M, Wolffenbuttel KP, Drop SL, Oosterhuis JW, Looijenga LH. Gonadal development and tumor formation at the crossroads of male and female sex determination. Sex Dev 2011;5:167–80.10.1159/000329477Search in Google Scholar PubMed
9. Hersmus R, de Leeuw BH, Wolffenbuttel KP, Drop SL, Oosterhuis JW, et al. New insights into type II germ cell tumor pathogenesis based on studies of patients with various forms of disorders of sex development (DSD). Mol Cell Endocrinol 2008;291:1–10.10.1016/j.mce.2008.02.028Search in Google Scholar PubMed
10. Hersmus R, Kalfa N, de Leeuw B, Stoop H, Oosterhuis JW, et al. FOXL2 and SOX9 as parameters of female and male gonadal differentiation in patients with various forms of disorders of sex development (DSD). J Pathol 2008;215:31–8.10.1002/path.2335Search in Google Scholar PubMed
11. Cools M, Drop SL, Wolffenbuttel KP, Oosterhuis JW, Looijenga LH. Germ cell tumors in the intersex gonad: old paths, new directions, moving frontiers. Endocr Rev 2006;27:468–84.10.1210/er.2006-0005Search in Google Scholar PubMed
12. Dumic M, Jukic S, Batinica S, Ille J, Filipovic-Grcic B. Bilateral gonadoblastoma in a 9-month-old infant with 46,XY gonadal dysgenesis. J Endocrinol Invest 1993;16:291–3.10.1007/BF03348838Search in Google Scholar PubMed
13. Fallat ME, Donahoe PK. Intersex genetic anomalies with malignant potential. Curr Opin Pediatr 2006;18:305–11.10.1097/01.mop.0000193316.60580.d7Search in Google Scholar
14. Michala L, Goswami D, Creighton SM, Conway GS. Swyer syndrome: presentation and outcomes. BJOG 2008;115:737–41.10.1111/j.1471-0528.2008.01703.xSearch in Google Scholar
15. Cools M, Looijenga LH, Wolffenbuttel KP, T’Sjoen G. Managing the risk of germ cell tumourigenesis in disorders of sex development patients. Endocr Dev 2014;27:185–96.10.1159/000363642Search in Google Scholar
16. McCann-Crosby B, Mansouri R, Dietrich JE, McCullough LB, Sutton VR, et al. State of the art review in gonadal dysgenesis: challenges in diagnosis and management. Int J Pediatr Endocrinol 2014;2014:4.10.1186/1687-9856-2014-4Search in Google Scholar
17. MacLaughlin DT, Donahoe PK. Sex determination and differentiation. N Engl J Med 2004;350:367–78.10.1056/NEJMra022784Search in Google Scholar
18. Douglas G, Axelrad ME, Brandt ML, Crabtree E, Dietrich JE, et al. Consensus in guidelines for evaluation of DSD by the texas children’s hospital multidisciplinary gender medicine team. Int J Pediatr Endocrinol 2010;2010:919707.10.1186/1687-9856-2010-919707Search in Google Scholar
19. Patel PR, Pappas J, Arva NC, Franklin B, Brar PC. Early presentation of bilateral gonadoblastomas in a Denys-Drash syndrome patient: a cautionary tale for prophylactic gonadectomy. J Pediatr Endocrinol Metab 2013;26:971–4.10.1515/jpem-2012-0409Search in Google Scholar
20. Olsen MM, Caldamone AA, Jackson CL, Zinn A. Gonadoblastoma in infancy: indications for early gonadectomy in 46XY gonadal dysgenesis. J Pediatr Surg 1988;23:270–1.10.1016/S0022-3468(88)80738-3Search in Google Scholar
21. Wunsch L, Holterhus PM, Wessel L, Hiort O. Patients with disorders of sex development (DSD) at risk of gonadal tumour development: management based on laparoscopic biopsy and molecular diagnosis. BJU Int 2012;110:E958–65.10.1111/j.1464-410X.2012.11181.xSearch in Google Scholar
22. Carillo AA, Damian M, Berkovitz G. Disorders of sexual differantiation. In: Lifshitz F, editor. Pediatric endocrinology. New York: Informa Healthcare, 2013:365–90.Search in Google Scholar
23. Manuel M, Katayama PK, Jones HW Jr. The age of occurrence of gonadal tumors in intersex patients with a Y chromosome. Am J Obstet Gynecol 1976;124:293–300.10.1016/0002-9378(76)90160-5Search in Google Scholar
24. Lindhardt Johansen M, Hagen CP, Rajpert-De Meyts E, Kjaergaard S, Petersen BL, et al. 45,X/46,XY mosaicism: phenotypic characteristics, growth, and reproductive function – a retrospective longitudinal study. J Clin Endocrinol Metab 2012;97:E1540–9.10.1210/jc.2012-1388Search in Google Scholar
25. Martinerie L, Morel Y, Gay CL, Pienkowski C, de Kerdanet M, et al. Impaired puberty, fertility, and final stature in 45,X/46,XY mixed gonadal dysgenetic patients raised as boys. Eur J Endocrinol 2012;166:687–94.10.1530/EJE-11-0756Search in Google Scholar
26. Gourlay WA, Johnson HW, Pantzar JT, McGillivray B, Crawford R, et al. Gonadal tumors in disorders of sexual differentiation. Urology 1994;43:537–40.10.1016/0090-4295(94)90251-8Search in Google Scholar
27. Robboy SJ, Miller T, Donahoe PK, Jahre C, Welch WR, et al. Dysgenesis of testicular and streak gonads in the syndrome of mixed gonadal dysgenesis: perspective derived from a clinicopathologic analysis of twenty-one cases. Hum Pathol 1982;13:700–16.10.1016/S0046-8177(82)80292-XSearch in Google Scholar
28. Rocha VB, Guerra-Junior G, Marques-de-Faria AP, de Mello MP, Maciel-Guerra AT. Complete gonadal dysgenesis in clinical practice: the 46,XY karyotype accounts for more than one third of cases. Fertil Steril 2011;96:1431–4.10.1016/j.fertnstert.2011.09.009Search in Google Scholar
29. Scully RE. Gonadoblastoma; a gonadal tumor related to the dysgerminoma (seminoma) and capable of sex-hormone production. Cancer 1953;6:455–63.10.1002/1097-0142(195305)6:3<455::AID-CNCR2820060303>3.0.CO;2-USearch in Google Scholar
30. Kriplani A, Agarwal N, Parul, Sharma MC, Manchanda R. Bilateral seminomas in a 45X/46XY mosaic with Turner’s phenotype: an unusual case of mixed gonadal dysgenesis. J Obstet Gynaecol Res 2003;29:63–6.10.1046/j.1341-8076.2003.00028.xSearch in Google Scholar
31. Cools M, Pleskacova J, Stoop H, Hoebeke P, Van Laecke E, et al. Gonadal pathology and tumor risk in relation to clinical characteristics in patients with 45,X/46,XY mosaicism. J Clin Endocrinol Metab 2011;96:E1171–80.10.1210/jc.2011-0232Search in Google Scholar
32. Verp MS, Simpson JL. Abnormal sexual differentiation and neoplasia. Cancer Genet Cytogenet 1987;25:191–218.10.1016/0165-4608(87)90180-4Search in Google Scholar
33. El Moussaif N, Haddad NE, Iraqi N, Gaouzi A. 45,X/46,XY mosaicisme: report of five cases and clinical review. Ann Endocrinol (Paris) 2011;72:239–43.10.1016/j.ando.2011.04.009Search in Google Scholar
34. Oliveira RM, Verreschi IT, Lipay MV, Eca LP, Guedes AD, et al. Y chromosome in Turner syndrome: review of the literature. Sao Paulo Med J 2009;127:373–8.10.1590/S1516-31802009000600010Search in Google Scholar
35. Hovatta O. Ovarian function and in vitro fertilization (IVF) in Turner syndrome. Pediatr Endocrinol Rev 2012;9(Suppl 2): 713–7.Search in Google Scholar
36. Saenger P. Turner syndrome. In: Sperling MA, editor. Pediatric endocrinology. Philadelphia: Saunders Elsevier, 2008: 610–61.Search in Google Scholar
37. Sallai A, Solyom J, Dobos M, Szabo J, Halasz Z, et al. Y-chromosome markers in Turner syndrome: Screening of 130 patients. J Endocrinol Invest 2010;33:222–7.10.1007/BF03345783Search in Google Scholar
38. Mazzanti L, Cicognani A, Baldazzi L, Bergamaschi R, Scarano E, et al. Gonadoblastoma in turner syndrome and Y-chromosome-derived material. Am J Med Genet A 2005;135:150–4.10.1002/ajmg.a.30569Search in Google Scholar
39. Mendes JR, Strufaldi MW, Delcelo R, Moises RC, Vieira JG, et al. Y-chromosome identification by PCR and gonadal histopathology in Turner’s syndrome without overt Y-mosaicism. Clin Endocrinol (Oxf) 1999;50:19–26.10.1046/j.1365-2265.1999.00607.xSearch in Google Scholar
40. Wiersma R. The clinical spectrum and treatment of ovotesticular disorder of sexual development. Adv Exp Med Biol 2011;707:101–3.10.1007/978-1-4419-8002-1_21Search in Google Scholar
41. Deans R, Creighton SM, Liao LM, Conway GS. Timing of gonadectomy in adult women with complete androgen insensitivity syndrome (CAIS): patient preferences and clinical evidence. Clin Endocrinol(Oxf) 2012;76:894–8.10.1111/j.1365-2265.2012.04330.xSearch in Google Scholar
42. Hughes IA, Davies JD, Bunch TI, Pasterski V, Mastroyannopoulou K, et al. Androgen insensitivity syndrome. Lancet 2012;380: 1419–28.10.1016/S0140-6736(12)60071-3Search in Google Scholar
43. George MM, New MI, Ten S, Sultan C, Bhangoo A. The clinical and molecular heterogeneity of 17 beta HSD-3 enzyme deficiency. Horm Res Paediatr 2010;74:229–40.10.1159/000318004Search in Google Scholar PubMed
44. Brooke AM, Taylor NF, Shepherd JH, Gore ME, Ahmad T, et al. A novel point mutation in P450c17 (CYP17) causing combined 17alpha-hydroxylase/17,20-lyase deficiency. J Clin Endocrinol Metab 2006;91:2428–31.10.1210/jc.2005-2653Search in Google Scholar PubMed
45. Han TS, Goswami D, Trikudanathan S, Creighton SM, Conway GS. Comparison of bone mineral density and body proportions between women with complete androgen insensitivity syndrome and women with gonadal dysgenesis. Eur J Endocrinol 2008;159:179–85.10.1530/EJE-08-0166Search in Google Scholar PubMed
46. Bertelloni S, Baroncelli GI, Mora S. Bone health in disorders of sex differentiation. Sex Dev. 2010;4:270–84.10.1159/000315961Search in Google Scholar
47. Dieckmann KP, Kulejewski M, Heinemann V, Loy V. Testicular biopsy for early cancer detection – objectives, technique and controversies. Int J Androl 2011;34:e7–13.10.1111/j.1365-2605.2011.01152.xSearch in Google Scholar
48. Elzinga-Tinke JE, Sirre ME, Looijenga LH, van Casteren N, Wildhagen MF, et al. The predictive value of testicular ultrasound abnormalities for carcinoma in situ of the testis in men at risk for testicular cancer. Int J Androl 2010;33: 597–603.Search in Google Scholar
49. Kim W, Rosen MA, Langer JE, Banner MP, Siegelman ES, et al. US MR imaging correlation in pathologic conditions of the scrotum. Radiographics 2007;27:1239–53.10.1148/rg.275065172Search in Google Scholar
50. Nakhal RS, Hall-Craggs M, Freeman A, Kirkham A, Conway GS, et al. Evaluation of retained testes in adolescent girls and women with complete androgen insensitivity syndrome. Radiology 2013;268:153–60.10.1148/radiol.13121068Search in Google Scholar
51. Muller J, Skakkebaek NE, Ritzen M, Ploen L, Petersen KE. Carcinoma in situ of the testis in children with 45,X/46,XY gonadal dysgenesis. J Pediatr 1985;106:431–6.10.1016/S0022-3476(85)80670-3Search in Google Scholar
52. Muller J, Skakkebaek NE. Testicular carcinoma in situ in children with the androgen insensitivity (testicular feminisation) syndrome. Br Med J (Clin Res Ed) 1984;288:1419–20.10.1136/bmj.288.6428.1419-aSearch in Google Scholar
53. Dieckmann KP, Skakkebaek NE. Carcinoma in situ of the testis: review of biological and clinical features. Int J Cancer 1999;83:815–22.10.1002/(SICI)1097-0215(19991210)83:6<815::AID-IJC21>3.0.CO;2-ZSearch in Google Scholar
54. Rajpert-De Meyts E. Developmental model for the pathogenesis of testicular carcinoma in situ: genetic and environmental aspects. Hum Reprod Update 2006;12:303–23.10.1093/humupd/dmk006Search in Google Scholar
©2015 by De Gruyter
